The treatment, Elahere, is only approved for ovarian cancer. The post New ovarian cancer treatment dubbed ‘biological missile ...
Massive Bio, a global leader in AI-driven precision oncology and clinical trial matching operating across 17+ countries, and ...
ADCs have become a core pillar of cancer treatment as increasingly sophisticated design is translating into stronger efficacy.
8d
Massive Bio to Unveil Reticulum Nexus™ as the AI Operating System for Oncology Access at ASCO 2026
Bridging cancer innovation and patient access through a trusted multi-agent platform. Cancer patients are not lost ...
BARCELONA, Spain--(BUSINESS WIRE)--Massive Bio, a global leader in artificial intelligence (AI) for cancer clinical trial enrollment, has announced the launch of Patient Connect, an innovative and ...
Targeted therapies and immunotherapies offer new treatment options for more types of cancer, but these drugs are less helpful when tumors produce multiple copies of a gene. This gene amplification ...
(Reuters) -The U.S. health regulator will not meet its Dec. 16 deadline to decide on the expanded use of Bristol Myers Squibb and partner 2seventy bio's blood cancer therapy in earlier lines of ...
This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study. Before the end of the ...
Cancer arises when the normal controls on cell growth, differentiation and death are subverted. Under physiological conditions, cells proliferate only in response to external stimuli, replicate their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results